PRPedro Henrique Reginato

Pedro Henrique Reginato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Henrique Reginato has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to: “INTERACT3 in Intensive Blood Pressure Meta‑Analysis: A Methodological Reappraisal”

    by Pedro Henrique Reginato, Henrique Alexsander Ferreira Neves, Leonardo Zumerkorn Pipek

  • Efficacy and safety of hemostatic net in facelift and rejuvenation surgeries (browlift and necklift): A systematic review and meta-analysis

    by Luiz Fábio Ribeiro, Lucas Rezende De Freitas, Ofonime Chantal Udoma-Udofa, Maísa de Souza Borges, Tauãna Terra Cordeiro de Oliveira, Pedro Henrique Reginato, Samyd S. Bustos, Lucas Kreutz-Rodrigues, Karim Bakri, Basel A. Sharaf


  • Response to “When Precision Meets Bias: Questioning the Validity of Pooled Estimates in Intensive Blood Pressure Lowering for Intracerebral Hemorrhage Meta-analyses”

    by Pedro Henrique Reginato, Gabriel Paulo Mantovani, Vinicius Furtado da Silva Castro, Giovanna Salema Pascual, Letícia Felício Saldanha, Henrique Alexsander Ferreira Neves, Leonardo Zumerkorn Pipek

  • Estimating Changes in Clinical Outcomes after Discontinuation of Anti-CGRP Targeting Therapy for Migraine Prophylaxis: A Systematic Review and Meta-analysis

    by Luana Miyahira Makita, Thales Pardini Fagundes, Pedro Henrique Reginato, Lucca Passow Carpinelli, Giovanna de Freitas Morais, Renata Trinkel Montanarin, Rafael de Freitas Kleimmann, Rafael Eduardo Streit, Aishwarya Koppanatham, Andressa Christine Sales Rodrigues, et al.

    Anti-calcitonin gene-related peptide (CGRP) therapies have significantly improved migraine prevention, but the long-term impact of discontinuation remains unclear. This systematic review and meta-analysis aimed to evaluate clinical outcomes following the cessation of anti-CGRP therapy. PubMed, Embase, and Cochrane databases were searched up to September 2024 for randomized or observational studies reporting post-discontinuation effects in patients with episodic or chronic migraine who had been preventively treated with anti-CGRP monoclonal antibodies or gepants. The primary outcome was the mean change in monthly migraine days from baseline to post-discontinuation. Secondary outcomes included acute headache medication use, the mean change in migraine frequency from active therapy to treatment cessation, and ≥ 50% responder rates. Heterogeneity was assessed with prediction intervals (PIs) for binary outcomes and I2 statistics for continuous data. Random-effects models pooled mean differences (MDs) and risk ratios (RRs), with subgroup analyses based on follow-up duration, study design, and individuals with chronic migraine. Eight studies (n = 1012) evaluating anti-CGRP monoclonal antibodies interruption were included. No studies on gepant cessation were found. Monthly migraine days decreased significantly post-discontinuation compared with baseline (MD -3.78; 95% CI -4.89, -2.67; I2 = 57%; p < 0.05), with reductions of - 5.70 days at 1 month and - 3.62 days at 3 months. Patients with chronic migraine showed sustained reductions (MD - 6.54; 95% CI - 8.64, - 4.43; I2 = 68%; p < 0.05) in the days per month with migraine between cessation and pre-treatment periods. Monthly acute headache medication days declined from baseline (MD - 1.74; 95% CI - 2.84, - 0.64; I2 = 0%; p < 0.05). Monthly migraine days increased at 3 months after discontinuation compared with just before discontinuation (MD 4.43; 95% CI 2.61, 6.25; I2 = 86%; p < 0.05), with monthly acute headache drug usage rising by 3.22 days. Responder rates of ≥ 50% declined (RR 0.42; 95% CI 0.33, 0.53; PI 0.17, 1.03; p < 0.05). Migraine burden worsened after discontinuation of anti-CGRP targeting therapies but remained lower than pretreatment levels. Further research is needed to explore disease-modifying potential and optimal discontinuation strategies. PROSPERO registration number CRD42024595771.


  • Intensive Blood Pressure Lowering for Intracerebral Hemorrhage: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials

    by Pedro Henrique Reginato, Gabriel Paulo Mantovani, Vinicius Furtado da Silva Castro, Giovanna Salema Pascual, Letícia Felício Saldanha, Henrique Alexsander Ferreira Neves, Leonardo Zumerkorn Pipek

    Background Intracerebral hemorrhage (ICH) is often associated with elevated blood pressure (BP), increasing the risk of persistent and recurrent hemorrhage, disability, and death. Previous studies have reported conflicting results regarding BP management, particularly concerning treatment timing and optimal targets. The aim of this review was to perform a systematic review and meta-analysis comparing intensive BP lowering with standard management in patients with ICH. Methods PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) comparing intensive BP lowering (target < 140 mm Hg) with standard management in patients with ICH. Outcomes included good functional outcome (modified Rankin scale [mRS] score 0–2), poor functional outcome (mRS score 3–6), all-cause mortality, and substantial hematoma enlargement. Subgroup analyses assessed (1) BP target thresholds, (2) randomization window (< 6 h vs. ≥ 6 h from symptom onset), and (3) BP target type (systolic blood pressure based vs. mean arterial pressure based). All analyses were conducted based on risk ratios (RR) and 95% confidence intervals (CIs) using a random-effects model. Results Eleven RCTs (13,625 patients; 6,755 in the intensive group) were included. Intensive BP lowering was associated with a significant reduction in poor functional outcome (mRS score 3–6; RR 0.93, 95% CI 0.90–0.96; p < 0.01) and an increase in good functional outcome (mRS score 0–2; RR 1.09, 95% CI 1.01–1.18; p = 0.03). All-cause mortality (RR 0.86, 95% CI 0.79–0.94; p < 0.01) and substantial hematoma enlargement (RR 0.83, 95% CI 0.73–0.95; p < 0.01) were also significantly lower in the intensive group. The subgroup analyses revealed no significant interactions. Conclusions These findings suggest that intensive BP lowering in ICH might be associated with improved functional outcomes and lower risks of death, disability, and hematoma enlargement, supporting its potential role in acute management.


  • Dorsal preservation versus dorsal reduction rhinoplasty techniques for aesthetic and functional outcomes: a systematic review and meta-analysis

    by Luiz Fábio Silva Ribeiro, Lucas Rezende De Freitas, Ofonime Chantal Udoma-Udofa, Rafael Mateus Correa, Pedro Henrique Reginato, Lucas Kreutz-Rodrigues, Uldis Bite, Karim Bakri


  • Incidence of aortic valve reintervention in patients with aortic stenosis undergoing transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and updated meta-analysis of randomized studies

    by Julia Goese Groberio, Pedro Henrique Reginato, Rafael Eduardo Streit, Alice Volpato Rocha, Ofonime Chantal Udoma-Udofa, Cynthia Florêncio de Mesquita, André Rivera, Anderson Zampier Ulbrich, Fábio Rocha Farias, Wilton Francisco Gomes

    Introduction Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) are established interventions for alleviating symptoms and enhancing survival in individuals with severe aortic stenosis (AS). However, the long-term outcomes and incidence of reintervention associated with TAVI and SAVR remain uncertain. Methods We conducted a systematic review and meta-analysis to compare the incidence of reintervention in TAVI versus SAVR. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs). Risk ratios (RR) and 95% confidence intervals (CI) were pooled with a random-effects model. A p-value < 0.05 was considered statistically significant. Results Nine RCTs were included, with 5144 (50.9%) patients randomized to TAVI. Compared with SAVR, TAVI increased reinterventions (RR 1.89; 95% CI 1.29–2.76; p < 0.01) and the need for pacemakers (RR 1.91; 95% CI 1.49–2.45; p < 0.01). In addition, TAVI significantly reduced the incidence of new-onset atrial fibrillation (RR 0.43; 95% CI 0.32- 0.59; p < 0.01). There were no significant differences in all-cause mortality (RR 1.04; 95% CI 0.92–1.16; p = 0.55), cardiovascular mortality (RR 1.04; 95% CI 0.94–1.17; p = 0.44), stroke (RR 0.97; 95% CI 0.80–1.17; p = 0.76), endocarditis (RR 0.96; 95% CI 0.70–1.33; p = 0.82), and myocardial infarction (RR 1.06; 95% CI 0.79–1.41; p = 0.72) between groups. Conclusions In patients with severe AS, TAVI significantly increased the incidence of reinterventions and the need for pacemakers as compared with SAVR.

  • Bromelain-Based Enzymatic Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis

    by Lucas Rezende de Freitas, Ofonime Chantal Udoma-Udofa, Pedro Henrique Reginato, Henrique Costa Mitsui, Henrique Provinciatto, Fabricio Carvalho Torres

    Deep burn injuries necessitate effective debridement to promote healing and reduce complications. Traditional surgical debridement is the standard of care; however, it can lead to significant tissue loss, excessive bleeding and delayed healing. Bromelain-based enzymatic debridement offers a potential less invasive alternative that aims to selectively remove necrotic tissue while preserving viable ones. Therefore, this systematic review and meta-analysis comprehensively compares bromelain debridement versus standard care in the management of partial and full-thickness burns. Cochrane Library, Embase, and Medline were searched until May 30th, 2024 for studies comparing bromelain debridement versus standard care. R version 4.4.0 was used to pooled risk ratio and mean difference in a random-effects model. We included seven studies, comprising 484 participants, of whom 238 (49%) were treated with enzymatic debridement. Bromelain significantly reduced time to eschar removal (MD - 7.60 days 95% CI [-9.76, -5.44]; I² = 70%) in comparison with standard care. Additionally, bromelain group presented a significant reduction in the risk of surgical excision (RR 0.17; 95% CI [0.06, 0.47]; I² = 79%) and need for autografts (RR 0.40; 95% CI [0.18, 0.93]; I² = 76%) in comparison with standard group. No differences were found in behalf of time to wound closure (MD -7.64; 95% CI [-18.46]-[3.18]; I2 = 86%), nor in Modified Vancouver Scar Scale (MD -0.36; 95% CI [-0.96]-[0.23]; I2 = 0%). Bromelain-based enzymatic debridement may accelerate eschar removal and reduce the need for surgical excision and autografts, without adversely affecting wound closure time or long-term scar quality.